Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 172

Sort by

Sort Order Select

Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Blood (2024) 144 (10): 1083–1092.

https://doi.org/10.1182/blood.2024023962

Published: 2024

Includes: Supplemental data

Journal Articles

What Interval of Daily Pain Assessment Is Required to Reliably Diagnose Chronic Pain in Sickle Cell Disease? the Pisces Study

Wally R Smith, Donna McClish

Blood (2023) 142 (Supplement 1): 252.

https://doi.org/10.1182/blood-2023-178065

Published: 2023

Journal Articles

A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community Benefit

Charles R. Jonassaint, Blaze Armon Eppinger, Dominique Friend, Golie Lorenzo Green, Mia Robinson, Teonna Woolford, DeMitrious Wyant, Janie Davis, Abdulafeez Oluyadi, Ahmar U Zaidi, Holly John, Wally R Smith

Blood (2023) 142 (Supplement 1): 2376.

https://doi.org/10.1182/blood-2023-186710

Published: 2023

Journal Articles

Incidence, Prevalence, and Disease Management Impactability of High Utilization in an Adult Sickle Cell Medical Home

Wally R Smith, Daniel Sop, Yue May Zhang, Benjamin Jaworowski, Shirley Johnson

Blood (2023) 142 (Supplement 1): 7206.

https://doi.org/10.1182/blood-2023-187621

Published: 2023

Journal Articles

Component-Specific Effects of Team Case Management on Adult Sickle Cell Utilization in Moderate to Low Utilizers

Shirley Johnson, Daniel Sop, Austin Hardy, Rachel Walls, Yue May Zhang, Benjamin Jaworowski, Wally R Smith

Blood (2023) 142 (Supplement 1): 7197.

https://doi.org/10.1182/blood-2023-187590

Published: 2023

Journal Articles

Quality of Care Among Emerging Adults with Sickle Cell Disease Using the Ascq-ME Qoc Measure: Baseline ST3P-up Study Data Results

Ifeyinwa Osunkwo, Myra Robinson, Anya Griffin, Azizi Coleman, Sharvil Desai, Padmaja Veeramreddy, Payal Desai, Charity Patterson, James Symanowski, Paulette Bryant, Jennifer Cornette, Wally R Smith, James R Eckman, Ramona Lawrence

Blood (2023) 142 (Supplement 1): 5048.

https://doi.org/10.1182/blood-2023-186835

Published: 2023

Journal Articles

Relative Influence of Biological Versus Behavioral Determinants of Utilization Among Adults with Sickle Cell Disease

Mica Ferlis, Daniel Sop, Yue May Zhang, Wally R Smith

Blood (2023) 142 (Supplement 1): 3680.

https://doi.org/10.1182/blood-2023-187483

Published: 2023

Journal Articles

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Andrius Zucenka, Ghayas C. Issa, Martha Arellano, Sajad Khazal, Nandita Khera, Wendy Stock, Branko Cuglievan, Yu Gu, Huy Van Nguyen, Angela R. Smith, Eytan M. Stein

Blood (2023) 142 (Supplement 1): 4950.

https://doi.org/10.1182/blood-2023-189036

Published: 2023

Journal Articles

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

Miguel R Abboud, Rodolfo D Cançado, Mariane De Montalembert, Wally R Smith, Hala Rimawi, Ersi Voskaridou, Birol Guvenc, Deborah Keefe, Kai Grosch, Michele L Nassin, Jimmy Watson, Justin Yssel, Evgeniya Reshetnyak, Yvonne Dei Adomakoh

Blood (2023) 142 (Supplement 1): 272.

https://doi.org/10.1182/blood-2023-185429

Published: 2023

Journal Articles

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

Blood (2023) 142 (Supplement 1): 271.

https://doi.org/10.1182/blood-2023-187033

Published: 2023

Journal Articles

Towards an Implicit Measure of Patient Engagement in Sickle Cell Disease: Relationships between Implicit Measures of Engagement and Previous Childhood Trauma Among Adolescents and Young Adults

Haylee Hartzog, Shirley Johnson, Rachel Walls, Yue May Zhang, Daniel Sop, Wally R Smith

Blood (2023) 142 (Supplement 1): 7319.

https://doi.org/10.1182/blood-2023-187552

Published: 2023

Journal Articles

Inpatient Reliance Ratio Versus Emergency Department Reliance Ratio in a Sickle Cell Disease Medical Home

Daniel M Sop, Yue May Zhang, Shirley Johnson, Benjamin Jaworowski, Wally R Smith

Blood (2022) 140 (Supplement 1): 7881–7882.

https://doi.org/10.1182/blood-2022-170137

Published: 2022

Journal Articles

Sickle Cell Disease May Qualify As an Ambulatory Care Sensitive Condition

Wally R Smith, Yue May Zhang, Shirley Johnson, Daniel M Sop

Blood (2022) 140 (Supplement 1): 7862–7863.

https://doi.org/10.1182/blood-2022-169474

Published: 2022

Journal Articles

Expansion of Content in the Phenx Toolkit for Sickle Cell Disease Pain

Stephanie H Guarino, Mark D Nelms, David Williams, Amanda M. Brandow, C. Patrick Carroll, Nitya Bakshi, Claudia M Campbell, Deepika S. Darbari, Martha Kenney, Wally R Smith, Jennifer Stinson, William Zempsky, Wayne Huggins, Deborah Maiese, Tabitha Hendershot, Carol Hamilton

Blood (2022) 140 (Supplement 1): 8302–8304.

https://doi.org/10.1182/blood-2022-169277

Published: 2022

Journal Articles

Screening for Adverse Childhood Experiences (ACEs) As a Way to Predict Overdose Risk in Adult Sickle Cell Patients

Rachel Walls, Daniel M Sop, Yue May Zhang, Benjamin Jaworowski, Shirley Johnson, Wally R Smith

Blood (2022) 140 (Supplement 1): 13039–13040.

https://doi.org/10.1182/blood-2022-169541

Published: 2022

Journal Articles

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Blood (2022) 140 (Supplement 1): 186–188.

https://doi.org/10.1182/blood-2022-170381

Published: 2022

Journal Articles

Architecture and Early Construction of a Multi-Modal Oncology Registry for Follicular Lymphoma

Mitchell R Smith, Julie Dodds, Hetal Shah, Zoe Drymoussi, David Kennard, Steven Labkoff

Blood (2022) 140 (Supplement 1): 5228–5229.

https://doi.org/10.1182/blood-2022-170156

Published: 2022

Journal Articles

Second Generation Adeno-Associated Viral Vector Using a Novel Factor VIII Variant with Improved Secretion Achieves Higher Factor VIII Expression in Non-Human Primates

Giang N. Nguyen, Maria C. Seleme, Jonathan R. Lindgren, Allysen C. Henriksen, Amy Muehlmatt, Melanie McFadden, Geary R. Smith, Denise E. Sabatino

Blood (2022) 140 (Supplement 1): 1902–1903.

https://doi.org/10.1182/blood-2022-168340

Published: 2022

Journal Articles

Oxycodone Produces Antinociception, but Worsens Functional Behaviors, in Humanized Sickle Cell Disease Mice

Kennedy N Goldsborough, Molly Sonenklar, Kalpna Gupta, M Imad Damaj, Wally R Smith, Joyce Lloyd, Aron Lichtman

Blood (2022) 140 (Supplement 1): 5448–5449.

https://doi.org/10.1182/blood-2022-162675

Published: 2022

Journal Articles

Natural History of Pediatric Patients with Sickle Cell Disease and Concurrent Cerebral Vasculopathies: Report of 62 Cases from a Single Institution

Joanna E. Papadakis, Paulina Piwowarczyk, Daniel S. Weber, Anna L. Slingerland, Dylan S. Keusch, Matthew M. Heeney, Edward R. Smith, Alfred P. See, Natasha M. Archer

Blood (2022) 140 (Supplement 1): 5446–5447.

https://doi.org/10.1182/blood-2022-170784

Published: 2022

NARROW

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

What Interval of Daily Pain Assessment Is Required to Reliably Diagnose Chronic Pain in Sickle Cell Disease? the Pisces Study

A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community Benefit

Incidence, Prevalence, and Disease Management Impactability of High Utilization in an Adult Sickle Cell Medical Home

Component-Specific Effects of Team Case Management on Adult Sickle Cell Utilization in Moderate to Low Utilizers

Quality of Care Among Emerging Adults with Sickle Cell Disease Using the Ascq-ME Qoc Measure: Baseline ST3P-up Study Data Results

Relative Influence of Biological Versus Behavioral Determinants of Utilization Among Adults with Sickle Cell Disease

Revumenib Maintenance Therapy Following Revumenib-Induced Remission and Transplant

Efficacy, Safety, and Biomarker Analysis of 5 Mg and 7.5 Mg Doses of Crizanlizumab in Patients with Sickle Cell Disease: Primary Analyses from the Phase III STAND Study

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

Towards an Implicit Measure of Patient Engagement in Sickle Cell Disease: Relationships between Implicit Measures of Engagement and Previous Childhood Trauma Among Adolescents and Young Adults

Inpatient Reliance Ratio Versus Emergency Department Reliance Ratio in a Sickle Cell Disease Medical Home

Sickle Cell Disease May Qualify As an Ambulatory Care Sensitive Condition

Expansion of Content in the Phenx Toolkit for Sickle Cell Disease Pain

Screening for Adverse Childhood Experiences (ACEs) As a Way to Predict Overdose Risk in Adult Sickle Cell Patients

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Architecture and Early Construction of a Multi-Modal Oncology Registry for Follicular Lymphoma

Second Generation Adeno-Associated Viral Vector Using a Novel Factor VIII Variant with Improved Secretion Achieves Higher Factor VIII Expression in Non-Human Primates

Oxycodone Produces Antinociception, but Worsens Functional Behaviors, in Humanized Sickle Cell Disease Mice

Natural History of Pediatric Patients with Sickle Cell Disease and Concurrent Cerebral Vasculopathies: Report of 62 Cases from a Single Institution

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only